openPR Logo
Press release

Gout Treatment Market Set to Reach New Heights as Novel Personalised Therapies Emerge | DelveInsight

04-29-2025 01:54 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Gout Treatment Market Report

Gout Treatment Market Report

The gout market is expected to experience significant growth across the 7MM, driven by increasing prevalence rates, an aging population, and advancements in personalized medicine. Key companies contributing to this growth include XORTX Therapeutics, Dyve Biosciences, Olatec Therapeutics, Arthrosi Therapeutics, AstraZeneca, RxOmeg Therapeutics, Sorrento Therapeutics, and Shanton Pharma, among others.
DelveInsight's latest report, "Gout - Market Insight, Epidemiology and Market Forecast - 2032 [https://www.delveinsight.com/report-store/gout-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]," integrates robust epidemiological data with market trends, competitive landscape analysis, and patient journey assessments, offering valuable insights into the evolving treatment paradigm. The gout market within the 7MM-which includes the United States, EU5 (France, Germany, Italy, Spain, and the UK), and Japan-is projected to show notable growth with a respectable compound annual growth rate (CAGR) by 2032. This growth reflects the rising prevalence of gout, an aging demographic, and innovations in drug delivery systems and personalized medicine approaches.

Download the Gout Market report to understand which factors are driving the gout therapeutic market @ Gout Market Trends [https://www.delveinsight.com/sample-request/gout-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].

The report offers an in-depth epidemiological analysis and forecasts through 2032. Gout affects approximately 3-4% of adults in the United States, with men being more commonly affected than women. Moreover, gout prevalence increases with age. it is lowest among individuals aged 20 to 39 years and highest among those aged 80 years or older.

The treatment landscape for gout has evolved markedly, with multiple effective options available for both acute flares and long-term management. Current first-line therapies for acute attacks include nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, and corticosteroids. For chronic management, xanthine oxidase inhibitors like allopurinol and febuxostat remain the cornerstone treatments. ZURAMPICIS (AstraZeneca), a urate transporter inhibitor, is also used to treat patients with gout, by removing excess uric acid near joints. It is recommended only as an adjuvant with either allopurinol or febuxostat when these medications are not sufficient.

Discover evolving trends in the gout patient pool forecasts @ Gout Epidemiology Analysis [https://www.delveinsight.com/sample-request/gout-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].

DelveInsight's analysis indicates that several companies are launching clinical trials to explore new gout treatment options or enhance existing ones. The clinical development pipeline for gout includes drugs such as DYV700 (Dyve), AR882 (Arthrosi Therapeutics), DYV700 (Dyve Biosciences), Dapansutrile (Olatec Therapeutics) and XRx-026 (XORTX Therapeutics), among others.

In March 2025, XORTX Therapeutics (NASDAQ: XRTX) announced a Type B meeting with the FDA scheduled for late April 2025 to discuss its proprietary formulation, XRx-026, for gout treatment. Towards the close of March 2025, Shanton Pharma reported positive top-line results from a Phase IIb clinical trial of its investigational gout therapy, SAP-001, targeting patients who are unresponsive to existing treatments. These developments underscore the momentum in the gout treatment landscape.

Furthermore, in January 2025, Scilex Holding Company, a subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE), amended its license agreement with RxOmeg Therapeutics LLC (ROMEG) to obtain the exclusive rights to market and distribute GLOPERBA worldwide. Previously, in June 2022, Scilex had received marketing and distribution rights only for the US. GLOPERBA is the first liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

Unlock which gout emerging drug is expected to capture the largest market share in 7MM by 2032. Visit the Gout Drug Insights [https://www.delveinsight.com/sample-request/gout-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]

The evolving landscape of gout treatment reflects significant progress in addressing unmet medical needs through innovative therapies. Emerging biologics, advanced drug delivery systems, and personalized medicine approaches are poised to redefine treatment strategies for both acute flares and chronic disease management. As these therapies gain regulatory approval and enter the market, they hold promise for improved patient outcomes and enhanced quality of life.

Table of Contents

1. Report Introduction

2. Executive Summary of Gout Pain

3. Gout Pain Market Share at a glance

4. Executive Summary of Gout Pain

5. Key Events

6. Gout Epidemiology and Market Methodology

7. Gout Background and Overview

8. Gout Pain Epidemiology and Patient Population

9. Country-Wise: Epidemiology of Gout Pain

10. Patient Journey

11. Gout Marketed Therapies

12. Gout Emerging Therapeutics

13. Market Size of Gout Pain

14. Gout Unmet Needs

15. SWOT Analysis

16. KOL Views

17. Reimbursement and Market Access

18. Appendix

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Related Reports:

Gout Pipeline Insight [https://www.delveinsight.com/sample-request/gouty-arthritis-gout-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]

Gout Pipeline Insight provides comprehensive insights about the gout pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the gout companies, including Jiangsu Atom Bioscience and Pharmaceutical, LG Chem, Shanton Pharma, TWi Biotechnology, Olatec Therapeutics, JW Pharmaceutical, Revive Therapeutics, Hinova pharmaceuticals, Arthrosi Therapeutics, Dyve Biosciences, Jiangsu Atom Bioscience and Pharmaceutical, Swedish Orphan Biovitrum, Allen Pharmaceuticals, Teijin Pharma, AstraZeneca, R-Pharm, InventisBio, Sinovent, and Shenyang Sunshine Pharmaceutical, among others.

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=gout-treatment-market-set-to-reach-new-heights-as-novel-personalised-therapies-emerge-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Gout Treatment Market Set to Reach New Heights as Novel Personalised Therapies Emerge | DelveInsight here

News-ID: 3992888 • Views:

More Releases from ABNewswire

2025 Recap: Waterproof Bedding Innovations - Industry Trends and Best Practices
2025 Recap: Waterproof Bedding Innovations - Industry Trends and Best Practices
Introduction: How 2025 Redefined Waterproof Bedding The year 2025 unfolded as a transformative chapter for the waterproof bedding [https://www.meihumaterial.com/products/] industry. Innovations accelerated, materials evolved, and consumer expectations rose sharply. What once felt like a simple protective accessory matured into a category defined by comfort, intelligence, sustainability, and design finesse. Waterproof bedding was no longer just a shield-it became a vital component of modern sleep culture. This surge in advancement was driven by
How Providing Comprehensive Drawing Details Accelerates OEM Seal Quotes & Prototyping at King Rubber
How Providing Comprehensive Drawing Details Accelerates OEM Seal Quotes & Protot …
For OEM engineers and procurement specialists, navigating the custom sealing component journey-from initial quote to physical prototype-can be a race against the clock. At King Rubber Products Inc. [https://www.king-rubber.com/], we understand that time is a critical resource in your product development cycle. A common bottleneck in this process is incomplete or ambiguous drawing information. By partnering with us and providing a specific set of drawing details upfront, you can significantly
Yuchai YCK08-60 vs YCK09-60: Deep Technical Comparison with Global Heavy-Duty Engines
Yuchai YCK08-60 vs YCK09-60: Deep Technical Comparison with Global Heavy-Duty En …
In today's global heavy-duty engine market, competition has evolved beyond raw horsepower to encompass efficiency, emissions, and lifecycle reliability. As a leading Chinese manufacturer, Yuchai Group continues to set benchmarks in engine innovation. Among its newest generation of China VI-compliant engines, the YCK08-60 [https://www.nzhengine.com/yuchai-yck09-60-diesel-engine-400hp-1700n-m-china-vi-dump-trucks-product/] and YCK09-60 [https://www.nzhengine.com/yuchai-yck08-60-8l-diesel-engine-350-hp-china-vi-euro-vi-level-excellent-fuel-economy-product/] stand out as flagship models designed for trucks, buses, and construction machinery.This article provides an in-depth, factual comparison between these two engines and benchmarks
Air Circuit Breaker Working Principle - Industry Trends and Best Practices
Air Circuit Breaker Working Principle - Industry Trends and Best Practices
Image: https://ecdn6.globalso.com/upload/p/4498/image_other/2026-01/sjkw1-air-circuit-breaker-smart-protection.jpg The Core Mechanism: Physics In Action The protection logic of an air circuit breaker [https://www.mingriele.com/acb/] is rooted in fundamental physical laws. The SJKW1 series [https://www.mingriele.com/acb/] employs a dual defense system to handle different electrical faults. For overload conditions, the device utilizes the thermal effect of bimetallic strips. As current flows, heat accumulates and causes the strip to bend slowly, mimicking the thermal characteristics of cables to prevent false trips. In

All 5 Releases


More Releases for Gout

Chronic Gout Market Trends, Therapeutics, and Growth Opportunities
Chronic gout is a progressive form of arthritis characterized by elevated uric acid levels, leading to severe joint pain, inflammation, and long-term joint damage. This condition affects millions worldwide, often resulting in impaired mobility and reduced quality of life. With rising prevalence due to lifestyle changes, aging populations, and dietary habits, the Chronic Gout market is witnessing a surge in demand for advanced therapeutics, early diagnostics, and patient management solutions. Download
Chronic Gout Market Massive Growth opportunity Ahead
Introduction Chronic gout is a form of arthritis characterized by recurrent attacks of severe pain, swelling, and inflammation in the joints, often due to the accumulation of uric acid crystals. This condition typically affects the big toe but can also impact other joints, including the knees, elbows, and wrists. Uric acid, a by-product of purine metabolism, accumulates in the body due to overproduction or underexcretion by the kidneys, leading to hyperuricemia
Gout Market Innovations in Pain Management and Treatment
On April 08, 2025, Exactitude Consultancy., Ltd. announces the release of the report "Global Gout Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2034". The report is a detailed and comprehensive analysis presented by region and country, type and application. As the market is constantly changing, the report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many
Gout Therapeutics Market Analysis By Drug Class (Nonsteroidal Anti-inflammatory …
Report Summary The global gout therapeutics market was valued at USD 2.78 Billion in 2021 and is expected to grow at a CAGR of 13.7% during the forecast period 2023-2032. Gout Therapeutics Market Introduction The deposition of monosodium crystals (MSU) into the distal joints and peripheral tissues results in gout, an inflammatory arthritic disease. Gout is a typical type of painful inflammatory arthritis. One joint is typically affected at a time (often
Global Gout Drugs Market Analysis (2020-2025)
Global Info Research offers a latest published report on Gout Drugs Analysis and Forecast 2020-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Gout Drugs Concentrate players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years. Click to view the full report TOC, figure and tables: https://www.globalinforesearch.com/reports/371311/gout-drugs Market
Gout Therapeutics Market Emerging Trends And Forecast By 2025
Global Gout Therapeutics Market: Snapshot The objective of treatment during a severe gout attack involves suppressing inflammation and controlling pain. The treatment of inflammation and pain can be attained with non-steroidal anti-inflammatory drugs, colchicine, or corticosteroids. The line of treatment chosen that would be suitable depends on the co-morbid medical conditions of the patient, side effect profile, and other medications. Patients with multiple episodes of severe gout attacks every year or with